Found: 19
Select item for more details and to access through your institution.
Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 9, p. 1, doi. 10.2967/jnumed.124.267636
- By:
- Publication type:
- Article
Non-specific irreversible <sup>89</sup>Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using <sup>89</sup>Zr-immuno-PET.
- Published in:
- EJNMMI Research, 2024, v. 14, p. 1, doi. 10.1186/s13550-024-01079-5
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small- cell lung cancer . .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of<sup> 89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
First-in-human study of <sup>89</sup>Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261926
- By:
- Publication type:
- Article
Total-body PET and highly stable chelators together enable meaningful <sup>89</sup>Zr-antibody-PET studies up to 30 days post-injection.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.230961
- By:
- Publication type:
- Article
The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2019, v. 4, n. 1, p. 1, doi. 10.1186/s41181-019-0055-6
- By:
- Publication type:
- Article
Validation of simplified uptake measures against dynamic Patlak K<sub>i</sub> for quantification of lesional <sup>89</sup>Zr-Immuno-PET antibody uptake.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 7, p. 1897, doi. 10.1007/s00259-023-06151-1
- By:
- Publication type:
- Article
In memoriam: Marion Hendriks-de Jong.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
The NHance ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
- Published in:
- Biomedicines, 2021, v. 9, n. 6, p. 665, doi. 10.3390/biomedicines9060665
- By:
- Publication type:
- Article
89 Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs.
- Published in:
- Cancers, 2023, v. 15, n. 23, p. 5546, doi. 10.3390/cancers15235546
- By:
- Publication type:
- Article
The Race for Hydroxamate-Based Zirconium-89 Chelators.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4466, doi. 10.3390/cancers13174466
- By:
- Publication type:
- Article
How to obtain the image-derived blood concentration from <sup>89</sup>Zr-immuno-PET scans.
- Published in:
- EJNMMI Physics, 2024, v. 11, n. 1, p. 1, doi. 10.1186/s40658-024-00621-7
- By:
- Publication type:
- Article
Alpha-Synuclein PET Tracer Development—An Overview about Current Efforts.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 9, p. 847, doi. 10.3390/ph14090847
- By:
- Publication type:
- Article
B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
- Published in:
- Arthritis Research & Therapy, 2016, v. 18, p. 1, doi. 10.1186/s13075-016-1166-z
- By:
- Publication type:
- Article